Amyris (company)

Amyris, Inc. is a biotechnology company headquartered in Emeryville, California. Amyris's products include ingredients for cosmetics, flavors, and fragrances. Amyris owns three brands: Biossance and Pipette, for beauty and baby skincare, and Purecane, a sugar substitute. The company went public on NASDAQ on September 28, 2010 (AMRS).[1]

Amyris, Inc.
Public
Traded asNASDAQ: AMRS
Russell 2000 Index component
IndustryRenewable Fuels, Anti-Malaria, Renewable Chemicals, Renewable Products
Founded2003
HeadquartersEmeryville, California, USA
Key people
John Melo: CEO
Joel Cherry: President
Kathleen Valiasek: CFO
Eduardo Alvarez: COO
Nicole Kelsey: Gen.Counsel & Secretary
Revenue $143.4 million
Number of employees
300–350
Websitewww.amyris.com

Artemisinin

Artemisinin is a compound naturally found in the Chinese sweet wormwood plant effective in the treatment of malaria. Its production is hampered by difficult climate and agricultural conditions. Institute for OneWorld Health received a grant from the Bill and Melinda Gates Foundation to develop and produce non-seasonal, high-quality, affordable artemisinin, and engaged Amyris Biotechnologies and Sanofi to assist on certain parts of the project, which is near completion, based on technology from UC Berkeley, NRC Canada, and other sources.

Media coverage
  • Using Microbes to create the Next Generation of Fuels on CNN The Next List (February 2013)
  • A Better Biofuel on MIT Technology Review (April 2007)
  • Bets on Biotech on US News (November 2006)

References
  1. "Amyris, Inc. Chief Executive Officer to Ring the NASDAQ Stock Market Closing Bell". www.nasdaq.com. Retrieved 2020-06-30.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.